AGP Picks
View all

Arizona Business Watch: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Arizona Business Watch.

Press releases published on April 22, 2026

SLNO 13-DAY DEADLINE ALERT: Hagens Berman Alerts Soleno Therapeutics (SLNO) Investors to Securities Class Action Alleging Hyperphagia Drug Launch Disruptions – Hagens Berman
Century Next Financial Corporation Reports 1st Quarter 2026 Results
The 2026 NAB Show Wraps with Proof the Future of Media and Entertainment is Expanding Beyond Broadcasting
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Camping World Holdings, Inc. to Secure Counsel Before Important Deadline in Securities Class Action – CWH
Clearfield Sets Fiscal Second Quarter 2026 Earnings Call for Wednesday, May 6, 2026
SOUTHERN MISSOURI BANCORP REPORTS PRELIMINARY RESULTS FOR THIRD QUARTER OF FISCAL 2026; DECLARES QUARTERLY DIVIDEND OF $0.25 PER COMMON SHARE; CONFERENCE CALL SCHEDULED FOR THURSDAY, APRIL 23, AT 9:30 AM CENTRAL TIME
GROCERY OUTLET INVESTOR ALERT: Bragar Eagel & Squire, P.C. Reminds Grocery Outlet Holding Corp. (NASDAQ:GO) Investors that a Class Action Lawsuit Has Been Filed and Encourages Investors to Contact the Firm
SIMPLY GOOD FOODS ALERT: Bragar Eagel & Squire, P.C. is Investigating The Simply Good Foods Company on Behalf of Simply Good Foods Stockholders and Encourages Investors to Contact the Firm
ONEMAIN INVESTOR ALERT: Bragar Eagel & Squire, P.C. is Investigating OneMain Holdings, Inc. on Behalf of OneMain Stockholders and Encourages Investors to Contact the Firm
VERITONE INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Veritone, Inc. on Behalf of Veritone Stockholders and Encourages Investors to Contact the Firm
ROSEN, LEADING INVESTOR COUNSEL, Encourages Driven Brands Holdings Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – DRVN
Press Release: Sanofi and Regeneron’s Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria
Communiqué de presse :  Dupixent, développé par Sanofi et Regeneron, a été approuvé aux États-Unis comme étant le premier médicament biologique pour les jeunes enfants atteints d’urticaire chronique spontanée non contrôlée
 nCino Announces Nick Edwards as Managing Director for APAC
Dupixent® (dupilumab) Approved in the U.S. as the First Biologic Medicine for Young Children with Uncontrolled Chronic Spontaneous Urticaria (CSU)
TransUnion Applauds FHFA, HUD for Advancing VantageScore in Mortgage Lending
New Findings Point to a Proven Path Forward for California’s Permanent Supportive Housing
Oxford Square Capital Corp. Schedules First Quarter 2026 Earnings Release and Conference Call for April 29, 2026
AI GPU Rental Launches New AI-Driven Supercomputing to Simplify Bitcoin Passive Earnings
Hammond Power Solutions Announces First Quarter 2026 Financial Results Conference Call and Webcast Notification

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Arizona Business Watch

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.